Gut microbiome in non-alcoholic fatty liver disease

Grzegorz Boryczka; Ewa Kosiorowska; Jakub Świętek; Kaja Głowacka; Marek Waluga

doi:10.2478/pjph-2022-0002

Authors

Grzegorz Boryczka Department of Gastroenterology and Hepatology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland Author
Ewa Kosiorowska Department of Gastroenterology and Hepatology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland Author
Jakub Świętek Department of Gastroenterology and Hepatology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland Author
Kaja Głowacka Department of Gastroenterology and Hepatology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland Author
Marek Waluga Department of Gastroenterology and Hepatology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland Author

DOI:

https://doi.org/10.2478/pjph-2022-0002

Keywords:

gut microbiome, dysbiosis, non-alcoholic fatty liver disease , probiotics , eubiotics , prokinetics

Abstract

The human gut microbiome is composed of communities of bacteria, viruses and fungi. Bacteria live in each part of digestive tract, increasing their density and changing composition in distal parts. The composition of gut microbiome mainly depends on method of childbirth, age, gender, diet, stress, infections, alcohol intake, diurnal variation, smoking, drugs (antibiotics), physical activity. Dysbiosis is defined as an imbalance or maladaptation in the gut microbial community. This imbalance favors many pathological states and it could be due to some diseases. Non-alcoholic fatty liver disease (NAFLD) has become increasingly common in parallel with the increasing prevalence of obesity and other components of the metabolic syndrome. In year 2020, a more comprehensive new definition of NAFLD was proposed – fatty liver disease associated with metabolic dysfunction (MAFLD). NAFLD/MALFD will become the major form of chronic liver disease in adults and children and could become the leading indication for liver transplantation within a decade. An increased level of Bacteroidetes and decreased level of Firmicutes is observed in fatty liver disease. This imbalance favors the collection of energy and insulin resistance. The prevention and treatment of dysbiosis in NAFLD/MAFLD is essential.

The purpose of this review is an understanding related to the dysbiosis and non-alcoholic fatty liver disease in order to help physicians of different specialties in their clinical practice because of growing in population patients with metabolic syndrome and liver steatosis.

References

1. Flint HJ. The impact of nutrition on the human microbiome. Nutr Rev. 2012;70(1):10-13.

2. Grice EA, Segre JA. The human microbiome: „Our second genome”. Annu Rev Genomics Hum Genet. 2012;13:151-70.

3. Dominguez-Bello MG, Costello E, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. PNAS. 2010;107(26):11971-5.

4. Zhu X, Han Y, Du J, et al. Microbiota-gut-brain axis and the central nervous system. Oncotarget. 2017;8(32):53829-38.

5. Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45.

6. Eslam M, Newsome PN, Sarin SK, et al. A new definitione for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202-9.

7. Found Y, Waked I, Bollipo S, et al. What’s in a name? Renaming NAFLD to MAFLD. Liver Int. 2020;40:1254-61.

8. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877-87.

9. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002;50(5):585-8.

10. Zuwala-Jagiello J, Pazgan-Simon M, Simon K, et al. Serum endocan level in diabetes mellitus of patients with cirrhosis and risk of subsequent development of spontaneous bacterial peritonitis. J Physiol Pharmacol. 2019;70(3):399-405.

11. Yan-Lan F, Hong C, Chun-Lin W, Li L. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: From “two hit theory” to “multiple hit model”. World J Gastroenterol. 2018;24(27):2974-83.

12. Rosso N, Chavez-Tapia NC, Tiribelli C, Bellentani S. Translational approaches: From fatty liver to non-alcoholic steatohepatitis. World J Gastroenterol. 2014;20(27):9038-49.

13. Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: Pathophysiology and Management. Gastroenterol Clin North Am. 2016;45(4):639-52.

14. Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49(2):197-211.

15. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-5.

16. Wawrzynowicz-Syczewska M, Waszczyk A, Bander D, et al. PNPLA3 gene polymorphism and severity of liver steatosis and fibrosis. Arch Med Scie Civil Dis. 2021;6:31-5.

17. Luc K, Schramm-Luc A, Guzik TJ, Mikolajczyk TP. Oxidative stress and inflammatory markers in prediabetes and diabetes. J Physiol Pharmacol. 2019;70(6):1.

18. Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol. 2015;7(3):575-82.

19. Gottlieb A, Canbay A. Why bile acids are so important in non-alcoholic fatty liver disease (NAFLD) progression. Cells. 2019;8(11):1358.

20. Olsen I, Yamazaki K. Can oral bacteria affect the microbiome of the gut? Sci Rep. 2015;5:8096.

21. Hasan N, Yang H. Factors affecting the composition of the gut microbiota, and its modulation. Peer J. 2019;7:7502.

22. Redondo-Useros N, Nova E, González-Zancada N, Diaz LE, Gómez- Martinez S, Marcos A. Microbiota and lifestyle: A special focus on diet. Nutrients. 2020;12(6):1776.

23. Magne F, Gotteland M, Gauthier L, et al. The firmicutes/bacteroidetes ratio: A relevant marker of gut dysbiosis in obese patients? Nutrients. 2020;12(5):1474.

24. Konturek PC, Harsch IA, Konturek K, et al. Gut-liver axis: How do gut bacteria influence the liver? Med Sci (Basel). 2018;6(3):79.

25. Backhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regu-lates fat storage. Proc Natl Acad Sci USA. 2004;101:15718-23.

26. Backhed F, Manchester JK, Semenkovich CF, et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA. 2007;104:979-84.

27. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;21(7122): 1027-31.

28. Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013;62:1787-94.

29. Wang B, Jiang X, Cao M, et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. sci rep. 2016;6:32002.

30. Michail S, Lin M, Frey MR, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015; 91(2):1-9.

31. Zhu L, Baker SS, Gill C, et al. Characterisation of gut microbiomes in non-alcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601-9.

32. Boursier J, Mueller O, Barret M, et al. The severity of non-alcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764-75.

33. Xu R, Tao A, Zhang S, et al. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med. 2015;8:3924-34.

34. Ratziu V, de Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54:1011-9.

35. Szulińska M, Loniewski I, van Hemert S, et al. Dose-dependent effects of multispecies probiotic supplementation on the Lipopolysaccharide (LPS) level and cardiometabolic profile in obese postmenopausal women: A 12- week randomized clinical trial. Nutrients. 2018;15:10.

36. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37(2):343-50.

37. Seliverstov PS, Stanislav V, Radchenko LB, et al. Saccharomyces boulardii modulates the composition of the gut microbiota in patients with nonalcoholic fatty liver disease, thus preventing the progression of the disease. Eksp Klin Gastroenterol. 2018;4:4-18.

38. Nabavi S, Rafraf M, Somi MH, et al. Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease. J Dairy Sci. 2014;97(12):7386-7393.

39. Wegh CA, Geerlings SY, Knol J, et al. Postbiotics and their potential applications in early life nutrition and beyond. Int J Mol Sci. 2019;20(19):4673.

40. Żółkiewicz J, Marzec A, Ruszczyński M, Feleszko W. Postbiotics-A step beyond pre- and probiotics. Nutrients. 2020;12(8):2189.

41. Rose S, Nyiazov DM, Rossignol DA, et al. Clinical and molecular characteristics of mitochondrial dysfunction in autism spectrum disorder. Mol Diagn Ther. 2018;22(5):571-93.

42. Fuentes M, Lajo T, Carrión J, Cuñé J. Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. BJN. 2013;109(10):1866-72.

43. Abdel-Razik A, Mousa N, Shabana W, et al. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot. Eur J Gastroenterol Hepatol. 2018;30(10):1237-46.

44. Wijarnpreecha K, Lou S, Watthanasuntorn K, et al. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2020;32(5):601-8.

45. Kuang L, Zhou W, Jiang Y. Association of small intestinal bacterial overgrowth with nonalcoholic fatty liver disease in children: A meta-analysis. PLoS One. 2021;16(12):0260479.

46. Okubo H, Nakatsu Y, Sakoda H, et al. Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model. Am J Physiol Gastrointest Liver Physiol. 2015;308:151-8.

Gut microbiome in non-alcoholic fatty liver disease

Authors

DOI:

Keywords:

Abstract

References

Downloads

Published

Issue

Section

License